Veru Inc (VERU) advances its biopharmaceutical pipeline with promising clinical results while navigating financial hurdles ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...

Q1 2025 Management View Veru highlighted its transformation into a late clinical-stage biopharmaceutical company focusing on cardiometabolic and inflammatory diseases, with major developments in ...

Cash, cash equivalents, and restricted cash were $26.6M as of December 31, 2024 versus $24.9M as of September 30, 2024. “We are very excited ...

Inc. reported its Q1 FY2025 earnings, revealing a net loss per share of $0.06, which was better than the projected loss of $0.08. The company's revenue reached $3.2 million, surpassing the forecast of ...

Q1 2025 Earnings Conference Call February 13, 2025 8:00 AM ETCompany ParticipantsSam Fisch - Executive Director, Investor ...

Veru is one biotech that thinks it’s found an answer. The Miami-based company has been testing two doses of its oral selective androgen receptor modulator enobosarm in a phase 2b trial of 168 ...

Veru (NASDAQ:VERU – Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, February 6th. Analysts expect Veru to post earnings of ($0.08) per share and ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...